About: Brilaroxazine

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Brilaroxazine (developmental code names RP-5063 and RP-5000), also known as oxaripiprazole, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of August 2022, it is in phase III clinical trials for schizophrenia.

Property	Value
dbo:abstract	Brilaroxazine (developmental code names RP-5063 and RP-5000), also known as oxaripiprazole, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of August 2022, it is in phase III clinical trials for schizophrenia. (en) Brilaroxazin eller RP-5063 är en atypisk antipsykotika som utvecklats av Reviva Pharmaceuticals. Det gick in i klinisk prövning Fas III i maj 2015. Brilaroxazin har en kemisk struktur väldigt lik Aripiprazol (Abilify) men med ersättande av istället en kolatom så är det en syreatom. Det är också kemiskt besläktat med Brexpiprazol (Rexulti) och Kariprazin (Vraylar). Medlet är tänkt att behandla schizofreni, schizoaffektivt syndrom, depression, psykos under Alzheimers sjukdom, psykos under parkinsons sjukdom och hyperaktivitet vid autism. (sv)
dbo:casNumber	1239729-06-6 1708960-04-6 (hydrochloride)
dbo:drugbank	DB09226
dbo:fdaUniiCode	X8L60BA01I
dbo:pubchem	46861612
dbo:thumbnail	wiki-commons:Special:FilePath/Brilaroxazine.svg?width=300
dbo:wikiPageExternalLink	http://revivapharma.com/product_pipeline/ http://adisinsight.springer.com/drugs/800035778
dbo:wikiPageID	46753436 (xsd:integer)
dbo:wikiPageLength	9066 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1116580871 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Carbon dbr:Cariprazine dbc:5-HT7_antagonists dbc:Atypical_antipsychotics dbr:Psychosis dbr:Schizophrenia dbr:Partial_agonist dbr:Bipolar_disorder dbr:Brexpiprazole dbc:Benzoxazines dbc:D2-receptor_agonists dbr:Dopamine_transporter dbr:Investigational_New_Drug dbr:Neurotransmitter dbr:Psychomotor_agitation dbr:List_of_investigational_antidepressants dbr:List_of_investigational_antipsychotics dbc:Chloroarenes dbc:Experimental_drugs dbc:Lactams dbc:Piperazines dbr:Chemical_structure dbr:Oral_administration dbr:Major_depressive_disorder dbr:Clinical_trial dbr:Receptor_antagonist dbr:Pharmacodynamics dbr:Muscarinic_acetylcholine_receptor dbr:Autism dbc:5-HT1A_agonists dbr:5-HT1A_receptor dbr:5-HT1B_receptor dbr:5-HT2A_receptor dbr:5-HT2C_receptor dbr:5-HT3_receptor dbr:5-HT6_receptor dbr:5-HT7_receptor dbc:5-HT2A_agonists dbc:Serotonin_reuptake_inhibitors dbr:Alpha-1B_adrenergic_receptor dbr:Alpha-2_adrenergic_receptor dbr:Alzheimer's_disease dbr:Oxygen dbr:Parkinson's_disease dbr:Histamine_H1_receptor dbc:Dopamine_agonists dbr:Hydrochloride dbr:Aripiprazole dbr:Attention_deficit_hyperactivity_disorder dbr:Atypical_antipsychotic dbc:5-HT6_antagonists dbr:Affinity_(pharmacology) dbr:Dopamine dbr:D1_receptor dbr:D2_receptor dbr:D3_receptor dbr:D4_receptor dbr:D5_receptor dbr:Serotonin dbr:Serotonin_transporter dbr:Phases_of_clinical_research dbr:Norepinephrine_transporter dbr:Schizoaffective_disorder dbr:Ring_system_(chemistry) dbr:Quinolinone dbr:Benzoxazinone
dbp:c	22 (xsd:integer)
dbp:casNumber	1239729 (xsd:integer)
dbp:casSupplemental	1708960 (xsd:integer)
dbp:chemspiderid	64853808 (xsd:integer)
dbp:cl	2 (xsd:integer)
dbp:drugbank	DB09226 (en)
dbp:h	25 (xsd:integer)
dbp:iupacName	6 (xsd:integer)
dbp:legalUs	dbr:Investigational_New_Drug
dbp:n	3 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	46861612 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:smiles	C1CNC4=CCl (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	PMKMNTBZJOXTJW-UHFFFAOYSA-N (en)
dbp:synonyms	RP-5063; RP-5000; Oxaripiprazole (en)
dbp:title	dbr:Pharmacodynamics
dbp:titlestyle	background:#ccccff (en)
dbp:unii	X8L60BA01I (en)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Antipsychotics dbt:Adrenergic_receptor_modulators dbt:Drugbox dbt:Navboxes dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Fdacite dbt:Dopamine_receptor_modulators dbt:Histamine_receptor_modulators dbt:Monoamine_reuptake_inhibitors
dcterms:subject	dbc:5-HT7_antagonists dbc:Atypical_antipsychotics dbc:Benzoxazines dbc:D2-receptor_agonists dbc:Chloroarenes dbc:Experimental_drugs dbc:Lactams dbc:Piperazines dbc:5-HT1A_agonists dbc:5-HT2A_agonists dbc:Serotonin_reuptake_inhibitors dbc:Dopamine_agonists dbc:5-HT6_antagonists
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Brilaroxazine (developmental code names RP-5063 and RP-5000), also known as oxaripiprazole, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of August 2022, it is in phase III clinical trials for schizophrenia. (en) Brilaroxazin eller RP-5063 är en atypisk antipsykotika som utvecklats av Reviva Pharmaceuticals. Det gick in i klinisk prövning Fas III i maj 2015. Brilaroxazin har en kemisk struktur väldigt lik Aripiprazol (Abilify) men med ersättande av istället en kolatom så är det en syreatom. Det är också kemiskt besläktat med Brexpiprazol (Rexulti) och Kariprazin (Vraylar). Medlet är tänkt att behandla schizofreni, schizoaffektivt syndrom, depression, psykos under Alzheimers sjukdom, psykos under parkinsons sjukdom och hyperaktivitet vid autism. (sv)
rdfs:label	Brilaroxazine (en) Brilaroxazin (sv)
owl:sameAs	wikidata:Brilaroxazine dbpedia-sv:Brilaroxazine dbpedia-tr:Brilaroxazine https://global.dbpedia.org/id/2MrrE
prov:wasDerivedFrom	wikipedia-en:Brilaroxazine?oldid=1116580871&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Brilaroxazine.svg
foaf:isPrimaryTopicOf	wikipedia-en:Brilaroxazine
is dbo:wikiPageRedirects of	dbr:C22H25Cl2N3O3 dbr:RP5063 dbr:RP-5063 dbr:RP-5000 dbr:RP5000 dbr:RP_5000 dbr:RP_5063 dbr:Oxaripiprazole
is dbo:wikiPageWikiLink of	dbr:List_of_investigational_antidepressants dbr:List_of_investigational_antipsychotics dbr:List_of_investigational_attention_deficit_hyperactivity_disorder_drugs dbr:2,3-Dichlorophenylpiperazine dbr:C22H25Cl2N3O3 dbr:RP5063 dbr:RP-5063 dbr:RP-5000 dbr:RP5000 dbr:RP_5000 dbr:RP_5063 dbr:Oxaripiprazole
is foaf:primaryTopic of	wikipedia-en:Brilaroxazine